Shapiro, Robert E.
Muenzel, Eva Jolanda https://orcid.org/0009-0000-7929-3704
Nicholson, Robert A.
Zagar, Anthony J.
L. Reed, Michael
Buse, Dawn C.
Hutchinson, Susan
Ashina, Sait
Pearlman, Eric M.
Lipton, Richard B.
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 14 August 2024
Accepted: 25 September 2024
First Online: 2 November 2024
Declarations
:
: Robert E. Shapiro: Consulting: Eli Lilly and Company, Lundbeck, AbbVie/Allergan, Theranica. Michael L. Reed: Consulting, Research Grants: AbbVie/Allergan, Amgen, Eli Lilly and Company, GlaxoSmithKline, National Headache Foundation, Promius. Dawn C. Buse: Consulting, Honoraria, Research Grants: AbbVie/Allergan, Amgen, Biohaven, Collegium, Eli Lilly and Company, Teva. Susan Hutchinson: Consulting, Speaking, Honoraria: AbbVie/Allergan, Amgen, Biohaven, Currax, electroCore, Eli Lilly and Company, Impel, Lundbeck, Teva, Theranica, Upsher-Smith. Sait Ashina: Consulting, Teaching, Honoraria: AbbVie/Allergan, Biohaven Pharmaceuticals, Eli Lilly and Company, Impel NeuroPharma, Lundbeck, Satsuma, Percept, Teva, Theranica; Consulting and Advisory Board: Pfizer. Richard B. Lipton: Stock or options: Manistee Health; Consultant, Advisory Board Member, Honoraria from or research support: Abbvie (Allergan), American Academy of Neurology, American Headache Society, Aeon, Amgen, Biohaven, Biovision, Boston, Dr. Reddy’s (Promius), electroCore, Eli Lilly and Company, Equinox, GlaxoSmithKline, Grifols, Lundbeck, Merck, Pernix, Pfizer, Teva, Vector, Vedanta. E. Jolanda Muenzel, Robert A. Nicholson, Anthony J. Zagar, and Eric M. Pearlman: Employee/Shareholder: Eli Lilly and Company.
: The Sterling Institutional Review Board (IRB ID #6425–001) provided approval for this non-interventional, observational survey study. All respondents provided electronic informed consent to participate in a general health-related survey. This was a non-interventional, observational study and not registered with a clinical trials registry.